Tuberculosis Prevention Remains a Challenge Despite BCG Vaccine

Despite the existence of the Bacillus Calmette-Guérin (BCG) vaccine for approximately 100 years, tuberculosis (TB) remains a formidable public health challenge worldwide.

The BCG vaccine, while effective in preventing severe forms of TB in children, offers limited and inconsistent protection against pulmonary TB in adults, which is the most common and transmissible form of the disease.

Part of the difficulty in preventing TB stems from the disease’s complex nature. The bacterium responsible, Mycobacterium tuberculosis, can remain dormant in the body for years, making it hard to detect and treat proactively. This latent stage can reactivate later, leading to active TB disease.

Furthermore, the emergence of drug-resistant strains of TB, such as multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), complicates treatment and prevention efforts. These resistant forms require longer, more toxic, and expensive treatment regimens, often with lower success rates.

Efforts to develop more effective vaccines and diagnostic tools are ongoing, but translating scientific advancements into widespread, accessible prevention and control measures is a slow process. Challenges include funding, political will, and the need for sustained global commitment to tackle TB effectively.

Preventing TB requires a multi-pronged approach, including not only vaccination but also early diagnosis, effective treatment of both active and latent TB, and addressing social determinants that contribute to the spread of the disease, such as poverty and crowded living conditions.

Source: Daily Monitor (Uganda)